Our laboratory applies a variety of neurophysiologic techniques to explore normal and altered function in animal models and human clinical research. Experimental procedures include EEG, evoked potentials, ensemble and single unit recordings, current source density, and measures of whole nerve conduction velocity. Recently we have focused on developing sensitive biomarkers for the onset and progression of toxic neuropathies and seizure disorders. We have studied transgenic and mutant mice, models of diabetic neuropathy, compound-induced seizures, and demyelinating and iatrogenic deficits of central and peripheral nerve function. In parallel, we have participated in the “translation” of basic neuroscience principles to human clinical studies. We are currently involved in the design and conduct of multicenter Phase 1-4 clinical trials of experimental therapies intended to reduce or prevent diabetic and chemotherapy-induced neuropathies, to improve the treatment of chronic inflammatory demyelinating polyneuropathy, to explore treatment for ALS, and to monitor the modulation of pain
